Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Cardiovasc Ther. 2014 Aug;12(8):933-47. doi: 10.1586/14779072.2014.931223. Epub 2014 Jun 19.

Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.

Author information

  • 1Department of Cardiology, University Hospital of Sabadell (University Autònoma de Barcelona), Barcelona, Spain .

Abstract

In the majority of patients with non-valvular atrial fibrillation (AF) anticoagulation is required to reduce the risk of stroke. Although vitamin K antagonists effectively reduce the risk of stroke, they have many disadvantages that limit their use. Rivaroxaban is a new once-daily oral anticoagulant that overcomes some of these limitations (i.e., no monitoring of anticoagulant effect required and fixed doses can be prescribed). In recent AF studies, rivaroxaban was reported to be at least as effective as warfarin for the prevention of stroke or systemic embolism but with a lesser risk of fatal bleeding and intracranial hemorrhage. More recent data have confirmed the beneficial effects of rivaroxaban, as originally described, and irrespective of the history of previous stroke, heart failure, myocardial infarction, diabetes, moderate renal dysfunction or age. In the present review the authors discuss current evidence regarding the efficacy and safety of rivaroxaban in patients with non-valvular AF.

KEYWORDS:

ROCKET-AF; anticoagulation; antithrombotic therapy; atrial fibrillation; bleeding; hemorrhage; rivaroxaban; stroke

PMID:
24948333
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk